Apoptosis markers in children with metabolic-associated fatty liver disease: a preliminary study.

Abstract

Introduction: Metabolic-associated fatty liver disease (MAFLD) is a new disease definition. The development of hepatic steatosis is complex and may also be influenced by apoptotic mechanisms.

Aim: We aimed to assess serum concentrations of selected apoptosis markers, cytokeratin-18 fragments (M30) and agiopoietin-2 (Ang2) in children and adolescents with obesity and to evaluate the association of these parameters with paediatric MAFLD.

Material and methods: The prospective study included 76 overweight/obese children with suspected liver disease. MAFLD was diagnosed according to the latest consensus. The concentrations of M30 and Ang2 in serum were measured using an enzyme-linked immunosorbent assay (ELISA).

Results: Liver steatosis was diagnosed in abdominal ultrasound in 45 obese patients (59.2%) who were classified as the MAFLD group. Children with MAFLD had elevated levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-glutamyltransferase (GGT), uric acid and M30 in comparison to non-MAFLD children. M30 positively correlated with ALT, AST, GGT, uric acid, Ang2 and the stage of liver steatosis. In receiver operating characteristic (ROC) analysis, M30 (cut-off = 173.74 IU/ml with sensitivity = 76.9% and specificity = 69.6%) allowed overweight/obese patients with and without MAFLD to be differentiated.

Conclusions: Our results suggest that the mechanism of apoptosis may play an important role in the development of MAFLD in children. There is a need for further studies in children to determine whether the M30 concentration may be an indicator of MAFLD progression and whether inhibition of apoptosis may become one of the therapeutic options for this disease.